Lilly, Novo, Sanofi face pressure from lawmakers to clarify low-cost insulin programs

Sens. Mag­gie Has­san (D-NH) and Tina Smith (D-MN) are ask­ing the three ma­jor in­sulin man­u­fac­tur­ers — Eli Lil­ly, No­vo Nordisk, and Sanofi — to pro­vide more de­tails on how pa­tients can ac­cess their low-cost in­sulin pro­grams.

Ear­li­er this year, the com­pa­nies an­nounced plans to dras­ti­cal­ly slash the list prices for their in­sulin prod­ucts, and each com­pa­ny of­fers pa­tient as­sis­tance pro­grams to pro­vide in­sulin capped at $35 per month to el­i­gi­ble pa­tients. Those ac­tions fol­lowed the pas­sage of the In­fla­tion Re­duc­tion Act last year, which capped the out-of-pock­et in­sulin cost at $35 for Medicare Part D ben­e­fi­cia­ries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.